A Manhattan federal court has denied Bayer’s legal attempt to stop Johnson & Johnson from promoting claims that its prostate cancer medication reduces the risk of death by half.
U.S. District Judge Dale Ho issued the ruling Friday evening, determining that Bayer had little chance of proving its case on its merits. Bayer had argued that Johnson & Johnson’s marketing campaign for Erleada contained misleading information that was causing lasting damage and potentially undermining confidence in Bayer’s competing medication, Nubeqa.
The decision means Johnson & Johnson can continue its current advertising approach for the multibillion-dollar treatment while the underlying legal dispute continues.
